

Vidya Perera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6728536/publications.pdf>

Version: 2024-02-01

25
papers

881
citations

623574

14
h-index

642610

23
g-index

25
all docs

25
docs citations

25
times ranked

1414
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The assessment of frailty in older people in acute care. <i>Australasian Journal on Ageing</i> , 2009, 28, 182-188. | 0.4 | 181 |
| 2 | The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. <i>Age and Ageing</i> , 2008, 38, 156-162. | 0.7 | 171 |
| 3 | Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe. <i>Current Drug Metabolism</i> , 2012, 13, 667-678. | 0.7 | 66 |
| 4 | Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 1161-1168. | 1.2 | 58 |
| 5 | Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 462-476. | 1.1 | 53 |
| 6 | First-in-class human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. <i>Clinical and Translational Science</i> , 2022, 15, 330-342. | 1.5 | 45 |
| 7 | Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1075-1082. | 1.7 | 44 |
| 8 | Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. <i>Biomedical Chromatography</i> , 2010, 24, 1136-1144. | 0.8 | 40 |
| 9 | First-in-class human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 876-887. | 1.1 | 40 |
| 10 | Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1115-1137. | 1.5 | 34 |
| 11 | Terbinafine in Combination with Other Antifungal Agents for Treatment of Resistant or Refractory Mycoses: Investigating Optimal Dosing Regimens Using a Physiologically Based Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 48-54. | 1.4 | 34 |
| 12 | Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 1218-1223. | 2.6 | 16 |
| 13 | Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. <i>Clinical Pharmacokinetics</i> , 2022, 61, 857-867. | 1.6 | 16 |
| 14 | Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 800-814. | 1.1 | 15 |
| 15 | Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 319-323. | 1.1 | 14 |
| 16 | Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 65, 264-270. | 1.2 | 13 |
| 17 | Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor. <i>Cardiology and Therapy</i> , 2022, 11, 407-419. | 1.1 | 10 |
| 18 | A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1957-1966. | 1.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Prediction of plasma caffeine concentrations in young adolescents following ingestion of caffeinated energy drinks: a Monte Carlo simulation. <i>European Journal of Pediatrics</i> , 2015, 174, 1671-1678. | 1.3 | 7 |
| 20 | Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. <i>Scientific Reports</i> , 2022, 12, 5165. | 1.6 | 6 |
| 21 | Pharmacometrics: an underused resource in Australian clinical research. <i>Medical Journal of Australia</i> , 2014, 200, 82-83. | 0.8 | 4 |
| 22 | Serious adverse drug reactions to zolpidem: does impaired metabolic clearance and concurrent <scp>SSRI</scp>/<scp>SNRI</scp> use increase risk?. <i>Journal of Pharmacy Practice and Research</i> , 2016, 46, 139-142. | 0.5 | 3 |
| 23 | Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1013-1026. | 1.6 | 3 |
| 24 | Frailty Should be Assessed Using Validated Scales. <i>Drugs and Aging</i> , 2010, 27, 687. | 1.3 | 0 |
| 25 | High-Dose Olanzapine for Bipolar Depression. <i>primary care companion for CNS disorders, The</i> , 2014, 16, . | 0.2 | 0 |